Skip to main content

and
  1. Article

    Open Access

    Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

    T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documente...

    Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato in Nature Communications (2023)

  2. Article

    Open Access

    BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

    Acute B-lymphoblastic leukemia (B-ALL) is a malignant disease characterized by accumulation of clonal immature lymphocytes in the bone marrow and peripheral blood. The approval of BCR::ABL1 tyrosine kinase inh...

    Joseph Kauer, Melanie Märklin in Journal of Cancer Research and Clinical On… (2022)

  3. Article

    Open Access

    Identification of CD105 (endoglin) as novel risk marker in CLL

    Several genetic and clinical markers are established as prognostic factors in chronic lymphocytic leukemia (CLL). However, additional markers are needed for risk stratification. Flow cytometric analysis is a m...

    Sarah M. Greiner, Melanie Märklin, Samuel Holzmayer, Kübra Kaban in Annals of Hematology (2022)

  4. Article

    Open Access

    A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

    T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins1,2, combined with the Toll-...

    Jonas S. Heitmann, Tatjana Bilich, Claudia Tandler, Annika Nelde, Yacine Maringer in Nature (2022)

  5. Article

    Open Access

    CD105 (Endoglin) as negative prognostic factor in AML

    While several genetic and morphological markers are established and serve to guide therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional markers to better stratify patie...

    Joseph Kauer, Karolin Schwartz, Claudia Tandler in Scientific Reports (2019)

  6. Article

    Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

    An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Anna M. Paczulla, Kathrin Rothfelder, Simon Raffel, Martina Konantz in Nature (2019)

  7. No Access

    Article

    Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

    Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but subsequently die of relapse1 that is driven by chemotherapy-resistant leukaemic stem cells (LSCs)2,3. LSCs are defined by the...

    Anna M. Paczulla, Kathrin Rothfelder, Simon Raffel, Martina Konantz in Nature (2019)